英夫利西单抗生物类似药CT-P13皮下与静脉维持治疗炎症性肠病的随机对照试验
本研究在活动性溃疡性结肠炎或克罗恩病患者中比较CT-P13皮下与静脉维持治疗的药代动力学、疗效、安全性和免疫原性。W22谷浓度几何均值比显示皮下非劣于静脉,W30/W54临床缓解率及安全性、免疫原性总体相当。
要点
- CT-P13皮下维持治疗在W22谷浓度上非劣于静脉治疗。
- 两臂W30/W54临床缓解率及安全性、免疫原性总体相当。
- 静脉转皮下后疗效与安全性仍保持可比。
核心结论
- CT-P13皮下维持治疗在药代动力学上非劣于静脉治疗,且疗效、安全性和免疫原性总体相当,支持其用于炎症性肠病。
研究设计与样本
- 随机、多中心、开放标签、平行组1期研究,纳入50个中心的活动性溃疡性结肠炎或克罗恩病且未使用过TNF抑制剂的患者。
- W0/W2静脉诱导后按1:1随机接受CT-P13皮下每2周(W6至W54)或静脉每8周(W6至W22),W30时静脉组全部转为皮下每2周至W54。
- 皮下组66例,静脉组65例。
主要发现
- W22观察谷浓度几何均值比为1154.17%(90%CI 786.37-1694.00;皮下组n=59,静脉组n=57),达到非劣效。
- W30/W54临床缓解率两臂可比。
- 其他疗效、安全性和免疫原性评估(包括转换后)两臂大致相当。
关键数值与推荐
- 主要终点为W22观察谷浓度非劣效,若几何均值比双侧90%CI下限超过80%则结论成立。
- 溃疡性结肠炎入组要求总Mayo评分6-12分且内镜亚评分≥2。
- 克罗恩病入组要求克罗恩病活动指数220-450分。
临床怎么用
- CT-P13皮下维持治疗可作为炎症性肠病静脉治疗的替代方案。
- 由静脉转为皮下治疗时疗效、安全性和免疫原性保持可比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) vs intravenous CT-P13 (CT-P13 IV) in patients with inflammatory bowel disease (IBD). METHODS: This randomized, multicenter, open-label, parallel-group, phase 1 study enrolled tumor necrosis factor inhibitor-naïve patients with active ulcerative colitis (total Mayo score 6-12 points with endoscopic subscore ≥2) or Crohn's disease (Crohn's Disease Activity Index 220-450 points) at 50 centers. After CT-P13 IV induction at Week (W) 0/W2, patients were randomized (1:1) to receive CT-P13 SC every 2 weeks (q2w) from W6 to W54 or CT-P13 IV every 8 weeks from W6 to W22. At W30, all patients receiving CT-P13 IV switched to CT-P13 SC q2w until W54. The primary endpoint was noninferiority of CT-P13 SC to CT-P13 IV for observed predose CT-P13 concentration at W22 (Ctrough,W22), concluded if the lower bound of the 2-sided 90% confidence interval (CI) for the ratio of geometric least-squares means exceeded 80%. RESULTS: Overall, 66 and 65 patients were randomized to CT-P13 SC and CT-P13 IV, respectively. The primary endpoint of noninferiority was met with a geometric least-squares means ratio for Ctrough,W22 of 1154.17% (90% CI 786.37-1694.00; n = 59 [CT-P13 SC]; n = 57 [CT-P13 IV]). W30/W54 clinical remission rates were comparable between arms. Other efficacy, safety, and immunogenicity assessments were also broadly comparable between arms, including after switching. CONCLUSIONS: The pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, and the comparable efficacy, safety, and immunogenicity profiles, support the potential suitability of CT-P13 SC treatment in IBD. ClinicalTrials.gov ID: NCT02883452.
引用
- Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021. PMID: 33676969. doi:10.1053/j.gastro.2021.02.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。